Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biora Therapeutics, Inc. - Common Stock
(NQ:
BIOR
)
0.6600
+0.0200 (+3.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biora Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
June 11, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
May 06, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
April 30, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
April 08, 2024
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 03, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 01, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
February 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
January 22, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Outlook for 2024
January 16, 2024
Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
December 18, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
December 11, 2023
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
November 06, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Submit Updated IND Application for BT-600
October 23, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
October 05, 2023
Autonomous next-gen device exceeded performance targets in three recent preclinical studies
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
September 25, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
September 19, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.